Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 5, 2009, Pages 993-999

  Izbicka, E ^a   Diaz, A ^a   Streeper, R ^a   Wick, M ^a   Campos, D ^a   Steffen, R ^b   Saunders, M ^b  

^a University of Texas Health Science Center at San Antonio   (United States)

^b Allos Therapeutics Inc   (United States)

Author keywords

Antifolates; Dihydrofolate reductase (DHFR); Non small cell lung cancer; Polyglutamylation; Pralatrexate; Xenograft

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; PEMETREXED; PRALATREXATE; RECOMBINANT ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TUMOR LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR XENOGRAFT;

AMINOPTERIN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; KINETICS; METHOTREXATE; NEOPLASMS; POLYGLUTAMIC ACID; TETRAHYDROFOLATE DEHYDROGENASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69049101976     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0954-4     Document Type: Article

References (24)

1. OA O'Connor PA Hamlin C Portlock CH Moskowitz A Noy DJ Straus B Macgregor-Cortelli E Neylon D Sarasohn O Dumetrescu et al. 2007 Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma Br J Haematol 139 3 425 428
2. FM Sirotnak JI DeGraw DM Moccio LL Samuels LJ Goutas 1984 New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties Cancer Chemother Pharmacol 12 1 18 25
3. Sirotnak FM, Schmid FA, Samuels LL, DeGraw JI (1987) 10-Ethyl-10-deaza- aminopterin: structural design and biochemical, pharmacologic, and antitumor properties. NCI Monogr (5):127-131
4. YG Assaraf 2007 Molecular basis of antifolate resistance Cancer Metastasis Rev 26 1 153 181
5. ES Chan BN Cronstein 2002 Molecular action of methotrexate in inflammatory diseases Arthritis Res 4 4 266 273
6. P Emery FC Breedveld S Hall P Durez DJ Chang D Robertson A Singh RD Pedersen AS Koenig B Freundlich 2008 Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial Lancet 372 9636 375 382
7. JA Wessels TW Huizinga HJ Guchelaar 2008 Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis Rheumatology (Oxford) 47 3 249 255
8. FM Sirotnak JI DeGraw WT Colwell JR Piper 1998 A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice Cancer Chemother Pharmacol 42 4 313 318
9. ES Wang O O'Connor Y She AD Zelenetz FM Sirotnak MA Moore 2003 Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression Leuk Lymphoma 44 6 1027 1035
10. LE Toner R Vrhovac EA Smith J Gardner M Heaney M Gonen J Teruya-Feldstein F Sirotnak OA O'Connor 2006 The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma Clin Cancer Res 12 3 Pt 1 924 932
11. LM Krug KK Ng MG Kris VA Miller W Tong RT Heelan L Leon D Leung J Kelly SC Grant et al. 2000 Phase I and pharmacokinetic study of 10-propargyl-10- deazaaminopterin, a new antifolate Clin Cancer Res 6 9 3493 3498
12. CG Azzoli LM Krug J Gomez VA Miller MG Kris MS Ginsberg R Henry J Jones L Tyson M Dunne et al. 2007 A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors Clin Cancer Res 13 9 2692 2698
13. LM Krug CG Azzoli MG Kris VA Miller NZ Khokhar W Tong MS Ginsberg E Venkatraman L Tyson B Pizzo et al. 2003 10-Propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer Clin Cancer Res 9 6 2072 2078
14. LM Krug RT Heelan MG Kris E Venkatraman FM Sirotnak 2007 Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma J Thorac Oncol 2 4 317 320
15. O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ, Dumetrescu O, Sarasohn D, Neylon E, Hamelers R et al et al. (2007) A Phase '2-1-2' study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies (abstract C85). AACR-NCI-EORTC international conference molecular targets and cancer therapeutics, p 283
16. E Izbicka D Campos G Carrizales A Patnaik 2005 Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro Anticancer Res 25 5 3215 3223
17. TJ Delcamp SS Susten DT Blankenship JH Freisheim 1983 Purification and characterization of dihydrofolate reductase from methotrexate-resistant human lymphoblastoid cells Biochemistry 22 3 633 639
18. B van Triest HM Pinedo Y van Hensbergen K Smid F Telleman PS Schoenmakers CL van der Wilt JA van Laar P Noordhuis G Jansen et al. 1999 Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines Clin Cancer Res 5 3 643 654
19. E Izbicka D Campos J Marty G Carrizales G Mangold A Tolcher 2006 Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models Anticancer Res 26 3A 1983 1988
20. A Gangjee HD Jain S Kurup 2007 Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I Anticancer Agents Med Chem 7 5 524 542
21. GJ Leclerc TA York T Hsieh-Kinser JC Barredo 2007 Molecular basis for decreased folylpoly-gamma-glutamate synthetase expression in a methotrexate resistant CCRF-CEM mutant cell line Leuk Res 31 3 293 299
22. E Liani L Rothem MA Bunni CA Smith G Jansen YG Assaraf 2003 Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines Int J Cancer 103 5 587 599
23. R Mauritz GJ Peters DG Priest YG Assaraf S Drori I Kathmann P Noordhuis MA Bunni A Rosowsky JH Schornagel et al. 2002 Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis Biochem Pharmacol 63 2 105 115
24. RC Cho PD Cole KJ Sohn G Gaisano R Croxford BA Kamen YI Kim 2007 Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells Mol Cancer Ther 6 11 2909 2920